R&D,Bioprocess,Clinical Development,Weekly Roundups,Biology

Weekly News Round-Up – 26/3/21

2 years ago By Charlotte Di Salvo

In the news this week, reports urge pharmaceutical companies to exploit the benefits of synthetic data in clinical trials. In other news, FDA fears over the safety of tanezumab compromises approval for the Pfizer/Lilly pain drug, and the COSMIC database promises great advancements in better matching treatment to patients’ cancer profiles.

FDA FEARS OVER SAFETY OF PFIZER/LILLY PAIN DRUG – Approval for tanezumab painkiller injection continues to be disputed with fear over the drug’s safety profile. This is not the first-time issues have been raised, with development suspended in 2012 due to issues with joint destruction. FDA reviewers are primarily focusing on the risk of Rapidly Progressive Osteoarthritis Rheumatology (RPOA) which has developed during trials with the pain drug. There is additional concern with mild nerve pain.

LATEST REPORTS REINFORCE BENEFITS OF SYNTHETIC DATA IN TRIALS – One of the main issues for clinical trials, especially in oncology, is the challenging and expensive recruitment process. According to a report by Accenture, synthetic data offers the opportunity to create a ‘synthetic patient profile’ as a virtual cohort. Using real-word evidence, synthetic data has the potential to accelerate progression of clinical trials by removing placebo effects. 

EXCITING DEVELOPMENTS IN PRECISION ONCOLOGY WITH COSMIC DATABASE – The launch of the Actionability tool for the COSMIC database allows clinicians and researchers to search over 37 million mutations across 1500 cancer types for the first time. Users can search for drugs that target specific mutations throughout the stages of drug development. With the addition of Actionability, clinicians can not only identify the mutations of a cancer, but how to precisely tailor the treatment for patients according to the genetic profile, from diagnosis through to therapy.

In other news:

R&D: 
Daiichi Sankyo digital partnership confirmed for Atrial Fibrillation research

CLINICAL:
Moderna initiates paediatric COVID-19 vaccine study

MANUFACTURING:
Vaccine rollout by J&J delivers only 22% of March target  

That’s all for now. See you next week!

Charlotte Di Salvo, Junior Medical Writer
Proventa International

More news

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies

Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups,Biology

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies

Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...

2 years ago

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups,Biology

RNA Therapeutics: The World’s First mRNA Malaria Vaccine

Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....

2 years ago

Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato

The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...

2 years ago
R&D,Bioprocess,Clinical Development,Weekly Roundups,Biology

Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato

The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...

2 years ago